Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABBV-321 |
| Synonyms | |
| Therapy Description |
ABBV-321 (serclutamab talirine) is an antibody-drug conjugate (ADC) consisting of a monoclonal EGFR antibody and the cytotoxic agent, pyrrolobenzodiazepine, which may lead to inhibition of tumor growth (PMID: 32847977). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABBV-321 | ABBV321|ABBV 321|Serclutamab talirine | EGFR Antibody 72 | ABBV-321 (serclutamab talirine) is an antibody-drug conjugate (ADC) consisting of a monoclonal EGFR antibody and the cytotoxic agent, pyrrolobenzodiazepine, which may lead to inhibition of tumor growth (PMID: 32847977). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03234712 | Phase I | ABBV-321 | A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands | Completed | USA | ISR | AUS | 0 |